[1]Castera L.Noninvasive methods to assess liver disease inpatients with hepatitis B or C[J].Gastroenterology, 2012, 142 (6) :1293-1302.e4.
|
[2]Colombo S, Belloli L, Zaccanelli M, et al.Normal liver stiff-ness and its determinants in healthy blood donors[J].DigLiver Dis, 2011, 43 (3) :231-236.
|
[3]Das K, Sarkar R, Ahmed SM, et al.“Normal”liver stiffnessmeasure (LSM) values are higher in both lean and obese in-dividuals:a population-based study from a developing coun-try[J].Hepatology, 2012, 55 (2) :584-593.
|
[4]Friedrich-Rust M, Ong MF, Martens S, et al.Performance oftransient elastography for the staging of liver fibrosis:a meta-analysis[J].Gastroenterology, 2008, 134 (4) :960-974.
|
[5]Zhu X, Wang LC, Chen EQ, et al.Prospective evaluation ofFibroScan for the diagnosis of hepatic fibrosis compared withliver biopsy/AST platelet ratio index and FIB-4 in patientswith chronic HBV infection[J].Dig Dis Sci, 2011, 56 (9) :2742-2749.
|
[6]Wong GL, Wong VW, Choi PC, et al.Development of a non-invasive algorithm with transient elastography (FibroScan) and serum test formula for advanced liver fibrosis in chronichepatitis B[J].Aliment Pharmacol Ther, 2010, 31 (10) :1095-1103.
|
[7]Castera L.Assessing liver fibrosis[J].Expert Rev Gastroen-terol Hepatol, 2008, 2 (4) :541-552.
|
[8]Cardoso AC, Carvalho-Filho RJ, Stern C, et al.Direct com-parison of diagnostic performance of transient elastography inpatients with chronic hepatitis B and chronic hepatitis C[J].Liver Int, 2012, 32 (4) :612-621.
|
[9]Kim SU, Park JY, Kim do Y, et al.Non-invasive assess-ment of changes in liver fibrosis via liver stiffness measure-ment in patients with chronic hepatitis B:impact of antiviraltreatment on fibrosis regression[J].Hepatol Int, 2010, 4 (4) :673-680.
|
[10]Gaia S, Carenzi S, Barilli AL, et al.Reliability of transientelastography for the detection of fibrosis in non-alcoholicfatty liver disease and chronic viral hepatitis[J].J Hepatol, 2011, 54:64-71.
|
[11]Wong GL, Wong VW, Chan HL.Is transient elastography in-accurate in chronic hepatitis B and non-alcoholic fatty liverdisease?[J].J Hepatol, 2011, 55 (2) :497.
|
[12]Castéra L, Vergniol J, Foucher J, et al.Prospective comparisonof transient elastography, Fibrotest, APRI, and liver biopsy forthe assessment of fibrosis in chronic hepatitis C[J].Gastroen-terology, 2005, 128 (2) :343-350.
|
[13]Castéra L, Sebastiani G, Le Bail B, et al.Prospective com-parison of two algorithms combining non-invasive methodsfor staging liver fibrosis in chronic hepatitis C[J].J Hepatol, 2010, 52 (2) :191-198.
|
[14]Roulot D, Costes JL, Buyck JF, et al.Transient elastogra-phy as a screening tool for liver fibrosis and cirrhosis in acommunity-based population aged over 45 years[J].Gut, 2011, 60 (7) :977-984.
|
[15]Foucher J, Chanteloup E, Vergniol J, et al.Diagnosis of cir-rhosis by transient elastography (FibroScan) :a prospectivestudy[J].Gut, 2006, 55 (3) :403-408.
|
[16]Vizzutti F, Arena U, Romanelli RG, et al.Liver stiffness measure-ment predicts severe portal hypertension in patients with HCV-related cirrhosis[J].Hepatology, 2007, 45 (5) :1290-1297.
|
[17]Sánchez-Conde M, Miralles P, Bellón JM, et al.Use oftransient elastography (FibroScanVR) for the noninvasiveassessment of portal hypertension in HIV/HCV-coinfectedpatients[J].J Viral Hep, 2011, 18:685-691.
|
[18]Kim do Y, Kim SU, Ahn SH, et al.Usefulness of FibroScanfor detection of early compensated liver cirrhosis in chronichepatitis B[J].Dig Dis Sci, 2009, 54 (8) :1758-1763.
|
[19]Robic MA, Procopet B, Métivier S, et al.Liver stiffness ac-curately predicts portal hypertension related complications inpatients with chronic liver disease:a prospective study[J].J Hepatol, 2011, 55:1017-1024.
|
[20]Merchante N, Rivero-Juárez A, Téllez F, et al.Liver stiff-ness predicts clinical outcome in human immunodeficiencyvirus/hepatitis C virus-coinfected patients with compensa-ted liver cirrhosis[J].Hepatology, 2012, 56 (1) :228-238.
|
[21]Corpechot C, Carrat F, Poujol-Robert A, et al.Noninvasiveelastography-based assessment of liver fibrosis progressionand prognosis in primary biliary cirrhosis[J].Hepatology, 2012, 56 (1) :198-208.
|
[22]Jung KS, Kim SU, Ahn SH, et al.Risk assessment of hepa-titis B virus-related hepatocellular carcinoma developmentusing liver stiffness measurement (FibroScan) [J].Hepatol-ogy, 2011, 53 (3) :885-894.
|
[23]Masuzaki R, Tateishi R, Yoshida H, et al.Prospective riskassessment for hepatocellular carcinoma development in pa-tients with chronic hepatitis C by transient elastography[J].Hepatology, 2009, 49 (6) :1954-1961.
|
[24]Jung KS, Kim SU, Choi GH, et al.Prediction of Recurrenceafter Curative Resection of Hepatocellular Carcinoma usingLiver Stiffness Measurement (FibroScan (?) ) [J].Ann SurgOncol, 2012, Jul 3.[Epub ahead of print]
|
[25]Wong GL, Wong VW, Choi PC, et al.Assessment of fibro-sis by transient elastography compared with liver biopsy andmorphometry in chronic liver diseases[J].Clin GastroenterolHepatol, 2008, 6 (9) :1027-1035.
|
[26] Wong GL, Wong VW, Choi PC, et al.Increased liver stiff-ness measurement by transient elastography in severe acuteexacerbation of chronic hepatitis B[J].J Gastroenterol Hep-atol, 2009, 24 (6) :1002-1007.
|
[27]Wong GL, Wong VW, Chim AM, et al.Factors associatedwith unreliable liver stiffness measurement and its failurewith transient elastography in the Chinese population[J].JGastroenterol Hepatol, 2011, 26 (2) :300-305.
|
[28]de Lédinghen V, Wong VW, Vergniol J, et al.Diagnosis ofliver fibrosis and cirrhosis using liver stiffness measurement:comparison between M and XL probe of FibroScan?[J].JHepatol, 2012, 56 (4) :833-839.
|
[1] | Qing ZHANG, Hai LI. Minutes of The Fifth (2021) Annual Meeting of APALD Tianjin Alliance and Digestion Forum (Continuing education class on the whole course management of portal hypertension in cirrhosis)[J]. Journal of Clinical Hepatology, 2021, 37(12): 2990-2992. doi: 10.3969/j.issn.1001-5256.2021.12.054 |
[2] | Xu JiaMin, Tang YingMei. Current status of research on bile duct lesions and related liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(4): 934-936. doi: 10.3969/j.issn.1001-5256.2019.04.051 |
[3] | Wu JunCheng, Xu MingYi. Research advances in the association between exosomes and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(9): 1815-1819. doi: 10.3969/j.issn.1001-5256.2017.09.042 |
[4] | Wang XiaoMing, Wang YueRen. Application of magnetic resonance imaging in hepatobiliary diseases and related challenges[J]. Journal of Clinical Hepatology, 2016, 32(12): 2231-2235. doi: 10.3969/j.issn.1001-5256.2016.12.002 |
[5] | Hu XianDa, Yue Ying, Wu Peng, Zhou Fei, Luo YuanDai. Research advances in pharmacological effects of Ophiacordyceps sinensis in treatment of liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(4): 793-797. doi: 10.3969/j.issn.1001-5256.2016.04.043 |
[6] | Huang LanYu, Xu LieMing. Relationship between liver diseases and autophagy[J]. Journal of Clinical Hepatology, 2014, 30(2): 186-188. doi: 10.3969/j.issn.1001-5256.2014.02.022 |
[7] | Lu LunGen, Li ZhengHong. Recent research on liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(5): 321-323. |
[8] | Chen Juan, Yin HuaBin. Clinical application of perfusion- weighted MRI in liver diseases[J]. Journal of Clinical Hepatology, 2013, 29(10): 793-796. doi: 10.3969/j.issn.1001-5256.2013.10.018 |
[9] | Zhang Qian, Han Tao. Research progress in advanced oxidation protein products in liver diseases[J]. Journal of Clinical Hepatology, 2013, 29(8): 581-584. doi: 10.3969/j.issn.1001-5256.2013.08.007 |
[10] | Wang JianShe. Development of a robust pediatric hepatology program to improve diagnosis and treatment of liver diseases in children[J]. Journal of Clinical Hepatology, 2012, 28(12): 881-883. |
[11] | Shen MeiRong, Li ZhongPing, Ding XiaoHong, Chu Feng, Hu DeChang. Clinical significance of liver biopsy in diagnosis and treatment of liver disease[J]. Journal of Clinical Hepatology, 2012, 28(7): 545-547. |
[12] | Liu Gang. Pediatric liver diseases associated with infection[J]. Journal of Clinical Hepatology, 2011, 27(7): 682-686. |
[13] | Xu Fang, Liu Jun, Gao PuJun. Severe liver injury with hyperthyroidism : a case report[J]. Journal of Clinical Hepatology, 2011, 27(10): 1096-1098. |
[14] | Liu GuoWang, Cao WuKui. Application of stem cells in liver disease treatment[J]. Journal of Clinical Hepatology, 2011, 27(9): 999-1002. |
[15] | Zheng Shan, Shen Zhen. Pediatric liver transplantation:present and future[J]. Journal of Clinical Hepatology, 2011, 27(7): 722-725. |
[16] | Tian Hui. Advances on the polycystic liver diseases[J]. Journal of Clinical Hepatology, 2011, 27(4): 446-449. |
[17] | Zhang Zhe, Guo JinSheng. The role of high mobility group box 1 in human liver diseases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1116-1120. |
[18] | Gao YanHang. Summary of symposium of translational medicine on liver disease[J]. Journal of Clinical Hepatology, 2011, 27(9): 1008-1009. |
[19] | Bai WenYuan, Liu Na. Prevention and thorough consideration of drug induced liver injury[J]. Journal of Clinical Hepatology, 2011, 27(3): 245-247. |